Literature DB >> 10642231

Systemic granulomatous disease after intravesical BCG instillation.

F C Mooren1, M M Lerch, H Ullerich, H Bürger, W Domschke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10642231      PMCID： PMC27269          DOI： 10.1136/bmj.320.7229.219

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

Review 1.  Tuberculosis.

Authors:  A Zumla; J Grange
Journal:  BMJ       Date:  1998-06-27

2.  BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics.

Authors:  A Lotte; O Wasz-Höckert; N Poisson; N Dumitrescu; M Verron; E Couvet
Journal:  Adv Tuberc Res       Date:  1984

3.  A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.

Authors:  D L Lamm; B A Blumenstein; E D Crawford; J E Montie; P Scardino; H B Grossman; T H Stanisic; J A Smith; J Sullivan; M F Sarosdy
Journal:  N Engl J Med       Date:  1991-10-24       Impact factor: 91.245

4.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450
  4 in total
  3 in total

1.  Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer.

Authors:  Heiko Schöder; Seng C Ong; Victor E Reuter; Shangde Cai; Eva Burnazi; Guido Dalbagni; Steven M Larson; Bernard H Bochner
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

2.  Bone marrow infection with bacillus Calmette-Guérin (BCG) after intravesical immunotherapy.

Authors:  Johannes Nemeth; Brigitte Stoiser; Heide-Maria Winkler; Leonard Müllauer; Wolfgang Graninger; Stefan Winkler
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

3.  Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer.

Authors:  S Lukacs; B Tschobotko; N A Szabo; Andrew Symes
Journal:  Case Rep Urol       Date:  2013-06-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.